Novartis's back-to-back trial failures reveal how thin the margin for error is in late-stage drug development

Novartis disclosed that two late-stage drugs failed their primary goals — a cholesterol therapy that lowered its target molecule but still couldn't reduce heart attacks, and a muscular dystrophy treatment that simply missed — marking the company's third pipeline disappointment in a single week.

The cholesterol drug's failure is the more unsettling result: lowering the biomarker wasn't enough to move the needle on actual patient outcomes, a finding that casts doubt on a whole class of drugs that rivals are also racing to develop.

ASML locking in TSMC and Samsung is the clearest sign yet that AI's chip hunger is structural, not a moment

ASML broke ground on a new manufacturing campus in the Netherlands and announced that both TSMC and Samsung have committed to adopting its most advanced chip-printing machines, with Samsung planning to deploy them for memory chips in 2028 and TSMC for cutting-edge processors in 2030.

When the two most powerful chipmakers on earth sign up years in advance for equipment that doesn't fully exist yet, it signals that demand for AI infrastructure is being treated as a long-term certainty, not a bet.

Meta's new AI agent is a harder sell to users who just watched the company pay $18 billion to settle a trust lawsuit

Meta launched a personal AI assistant called Muse that can send your emails, book your travel, and make payments on your behalf — and the company internally acknowledged concerns that the technology could mishandle sensitive personal information.

Asking users for deeper access to their private lives is a genuinely difficult pitch two weeks after Meta settled one of the largest social media harm lawsuits in history, and that tension is the real story behind an otherwise routine product launch.